LAUSR

ProtonDx will provide a response to the COVID-19 pandemic by bringing nucleic-acid based molecular diagnostics to the palm of your hand. It will support the deployment of the Lacewing technology, which achieves accurate, rapid, handheld and low cost detection of SARS-CoV-2 and other respiratory infections. Results are synchronized to electronic health records and geotagged for real-time surveillance of disease progression. The device was designed for use at the point of need, in places such as pharmacies, schools and workplaces. Its unique approach combines standard semiconductor technology, advanced molecular biology and 3D printed microfluidics to match the performance of a bench-based instrument. Clinical trials are currently in progress at Imperial NHS Trust, London, UK which will lead to regulatory approvals and commercialization in the next few months.